Sunday, 28 September 2014

A New Standard of Care in HER2 Breast Cancer

MADRID (MedPage Today) -- Adding two anti-HER2 agents to chemotherapy for metastatic disease increases media survival to almost 5 years. via MedPageToday.com - medical news plus CME for physicians Read More Here..


Lake forest health and fitness http://ift.tt/1ruAi3X

No comments:

Post a Comment